U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT07573059) titled 'Evaluation of the Safety of Loargys Arginine Test System in Loargys-treated Patients' on April 28.
Brief Summary: Arginase 1 deficiency (ARG1-D) is a rare condition in which the body cannot properly break down a substance called arginine. This leads to high levels of arginine and related substances in the blood, which can cause serious health problems and reduce quality of life.
Loargys is a new treatment designed to lower arginine levels in people with ARG1-D. It works by providing a modified version of a natural enzyme that breaks down arginine in the blood. The dose of Loargys is adjusted for each patient based on their arginine l...